abbvie glp-1 receptor agonist AbbVie Enters Obesity Field, Paying $350M for Amylin Already in How GLP-1 Receptor Agonists Evolved
Description
The graph represents the percentage of patients with type 2 diabetes observed in England in year of 2024
PLoS One 2014
Diabetes Metab 38(1):8688 Hogan AE et al (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis
There have been several head-to-head clinical trials comparing the efficacy of different GLP-1 receptor agonists broadly demonstrating the superiority of semaglutide to comparators [37]
Injection sites should be rotated weekly
PMID: 36629465
